explore -WSS

explore

author：focus 2025-09-27 13:11:04 - browse：71138

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Despite FDA concern, risk that CAR

explore

WSS

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Neuroscience renaissance leads to new crop of psychiatric drugs

Cholera vaccine supplies dangerously low, outbreaks surging

Neuroscience renaissance leads to new crop of psychiatric drugs

Doctor of U.S. President Joe Biden says he is fit for duty

UnitedHealth’s Optum accused of antitrust violations in California

hotspot

explore

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

ReNAgade cuts staff seven months after raising $300 million

Continuity nursing helped my family in our darkest PICU moments

Using force crossed my mind when examining a defiant young patient

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

23andMe had bad news about my health. I wish a person had delivered it

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Beam, Prozac, "TechBio" and more

focus

Cholera vaccine supplies dangerously low, outbreaks surging

With clinical trial data readouts, here's how to spot spin

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

CDC panel: People 65 and older should get a Covid spring booster shot

Study fuels hope CAR

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

explore

focus

explore

hotspot